Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.

Impact of Metformin Use on PFS of Patients with DM In patients diagnosed with DM prior to treatment initiation who received lanreotide, median PFS was not reached in those who were not receiving concomitant metformin, while median PFS was reached at 95.9 weeks in patients receiving metformin; however, this difference did not reach statistical significance (HR: 4.27 {95% CI 0.20–92.62}; p = 0.402; Figure S2A ).

also in 111,027 other papers